AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00829257
Drug: HFA-BDP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFA-BDP (Qvar) 100ug 2puff b.i.d
Trial: NCT00601796
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (300 mg/m\^2 IV) was administered before 1st and 4th vaccines to deplete regulatory T-cells.
Trial: NCT03701568
Drug: dC/dT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collection of retrospective data from TK2 patients previously treated with dC/dT
Trial: NCT02172508
Drug: Placebo Lactose Capsule
RxNorm normalized name: lactose Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01064037
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion during 48h
Trial: NCT00656591
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate
Trial: NCT01043666
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT04764058
Drug: Tienam 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem and cilastatin sodium
Trial: NCT04224428
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lactose oral tablet
Trial: NCT03955601
Drug: Haploidentical HSCT using TBI free regimen, ''ATG'' with ''Post transplant cyclophosphamide''
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ''Busulphan'' will be used in place of ''TBI'' in equivalent myelotoxic dose to facilitate engraftment , ''ATG'' will be used to reduce GVHD and facilitate engraftment while ''combine PBSC'' and/OR ''Bone marrow harvest'' will be used
Trial: NCT00391417
Drug: estradiol gel
RxNorm normalized name: ESTRADIOL 1 mg in 1 g TOPICAL GEL [Estradiol Gel]
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03774082
Drug: INC424
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib is taken orally either as 5mg tablets or as pediatric formulation (dosage based on age group)
Trial: NCT03589885
Drug: Placebo 2 mL auto-injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8.~PASI 90 responders at week 12: 2 mL auto-injector placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48.~PASI 90 non-responders at week 12: 2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48
Trial: NCT03589885
Drug: Placebo 1 mL prefilled syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8.~PASI 90 responders at week 12: 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48.~PASI 90 non-responders at week 12: 2x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48
Trial: NCT03519516
Drug: PRO-174
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: ophthalmic solution~* Prepared by: Laboratorios Sophia, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: sterile multi-dose bottle
Trial: NCT03519516
Drug: Sophixín Ofteno®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Active substance: Ciprofloxacin 0.3%~* Pharmaceutical form: Ophthalmic solution~* Prepared by: Laboratorios Sophia, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: sterile multi-dose bottle
Trial: NCT00171314
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 4 mg Intravenous (IV)15 minute infusion every 6 months.
Trial: NCT00042250
Drug: Chemotherapy for hematologic malignancy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01096043
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An infusion of an identically appearing solution of sugar water will be intravenously administered.
Trial: NCT02250612
Drug: 1 drop of 0.375% SYL040012 (bamosiran)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02250612
Drug: 1 drop of 0.750% SYL040012 (bamosiran)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02250612
Drug: 1 drop of 1.125% SYL040012 (bamosiran)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02250612
Drug: 1 drop of 1.5% SYL040012 (bamosiran)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03112382
Drug: zinc supplement plus vitamin A and E
RxNorm normalized name: vitamin A / vitamin E
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00896168
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX stable dose (7.5 to 20 mg/week equal to the dose used before participation in the study) for 22 weeks.
Trial: NCT00563108
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01238133
Drug: Gamma-Secretase Inhibitor RO4929097
RxNorm normalized name: .GAMMA.-OCTALACTONE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01086046
Drug: Low molecular weight heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin sodium injection 1mg/kg 2 times in 24 hour~Low molecular weight heparin sodium injection 1mg/kg 2 times per day in 3 days.
Trial: NCT03833999
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: overcoated placebo tablet, identical to the ondansetron
Trial: NCT00963365
Drug: AZD6765
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose and single IV infusion of AZD6765
Trial: NCT00963365
Drug: AZD6765
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily oral dose of AZD6765 or placebo on Day 1 and on Days 4 through 9.
Trial: NCT02804594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo taken three times daily
Trial: NCT01280487
Drug: ZSTK474
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral dosing for 21 days each cycle
Trial: NCT03510572
Drug: [18F]PI-2620
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imaging for evaluating the accumulation of abnormal tau protein in the brain
Trial: NCT00485589
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral repeating dose
Trial: NCT00485589
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT05008146
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous, 1mg/Kg
Trial: NCT00131677
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: study product taken daily
Trial: NCT01314976
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo.~1 treatment period of 1ml/kg/day for 10 days, 3 daily dosages. Administered by parents.~Placebo formulation is identical to Flagyl® (Metronidazole), oral suspension from Sanofi-Aventis.
Trial: NCT00274768
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A total of 115 cycles of therapy were administered and five patients did not complete cycle 1. The median number of cycles initiated was four (range 1-16).
Trial: NCT00871377
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: corn oil (n-6 fatty acids)
Trial: NCT04142749
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total 90mg, By mouth, TID
Trial: NCT01863277
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01863277
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02136277
Drug: Hartmann's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered in 250ml boluses, until cardiac output has been optimised.
Trial: NCT00613093
Drug: Temodar and O6-Benzylguanine (BG)
RxNorm normalized name: O6-benzylguanine
DrugBank: 6-O-benzylguanine (DB11919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Objectives of study are to define role of BG in restoring Temodar sensitivity in patients with Temodar-resistant malignant glioma and to further define the toxicity of combination therapy using Temodar + BG. 2 separate strata accrued independently of each other: Stratum 1-patients with glioblastoma multiforme (GBM). Stratum 2-patients with anaplastic glioma (AG).~BG at 120mg/m2 administered intravenously over 1 hour followed immediately by 48-hour infusion at 30mg/m2/24 hours. Temodar 472mg/m2 administered orally, in fasting state, within 60 minutes of end of the 1-hour administration of BG infusion. Treatment cycles may be repeated every 28 days following dose of Temodar from previous cycle.
Trial: NCT02376218
Drug: Hypertonic 50% dextrose pleurodesis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural administration of 180ml of hypertonic dextrose solution.
Trial: NCT01260350
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (SOF) tablets administered orally once daily
Trial: NCT01260350
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDV/SOF fixed-dose combination (FDC) tablet administered once daily
Trial: NCT01936064
Drug: Placebo + Cyclophosphamide - Epirubicin 6
RxNorm normalized name: epirubicin 0.6 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine drugs for the treatment of breast cancer to be used with Placebo
Trial: NCT00099788
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV to oral transition.
Trial: NCT01680978
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally daily, 6 weeks
Trial: NCT02405585
Drug: mFOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFIRINOX consisting of Oxaliplatin 85 mg/m\^2 IV over 2 hours; Irinotecan 180 mg/m\^2 IV over 90 minutes; Leucovorin 400 mg/m\^2 IV over 2 hours; Fluorouracil 2.4 g/m\^2 IV over 46 hours - given on days 15, 29, 43, 57, 71 and 85
Trial: NCT03369236
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo was administered as an oral tablet.
Trial: NCT00142493
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intralipid, saline, saline with multi-Vit solution
Trial: NCT02530307
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01490996
Drug: Chemotherapy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care chemotherapy
Trial: NCT02065336
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00961090
Drug: Aminolevulinic Acid
RxNorm normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg/kg mixed in 50cc water and taken orally 3 hours prior to surgery
Trial: NCT00568529
Drug: Capecitabine and Oxaliplatin
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000mg/m2 Bid d1-14 Oxaliplatin 130mg/m2 d1 q3w
Trial: NCT03255993
Drug: SPH3127 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPH3127 50mg
Trial: NCT03255993
Drug: SPH3127 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPH3127 100mg
Trial: NCT03255993
Drug: Placebo matching to SPH3127 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to SPH3127 50mg
Trial: NCT03255993
Drug: Placebo matching to SPH3127 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to SPH3127 100mg
Trial: NCT03466021
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching injection
Trial: NCT03991884
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03991884
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01404442
Drug: placebo(distilled water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
Trial: NCT01653158
Drug: CP-751,871
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-751,871 was given intravenously \[IV\] every 3 weeks in escalating doses ranging from 0.1 mg/kg up to 20 mg/kg.~Standard doses of Docetaxel were given every 3 weeks with CP-751,871. Study therapy was continued until disease progression, lack of tolerability for up to 17 cycles (approximately 1 year).
Trial: NCT00421603
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03983928
Drug: TQB2450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Trial: NCT00765128
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
Trial: NCT00765128
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
Trial: NCT03444870
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as per the schedule specified in the respective arm.
Trial: NCT04902534
Drug: placebo of Naoqingzhiming Tablets (without echinacoside)
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose escalation and multiple dose escalation
Trial: NCT03677817
Drug: NaCl 0,9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV bolus of NaCl 0,9%, followed by continuous infusion of NaCl 0,9%
Trial: NCT00848250
Drug: Angiotensin Converting Enzyme Inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to this group will continue their current dose of ACE inhibitors until surgery
Trial: NCT03497442
Drug: Placebo Vehicle Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Gel
Trial: NCT01170702
Drug: 0.9% Normal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
Trial: NCT02535832
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo CT Scan DXA scan Needle muscle biopsy
Trial: NCT00304317
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Take two capsules (400 mg) by mouth immediately, then take one capsule (200 mg) by mouth every 12 hours until gone.
Trial: NCT01343407
Drug: MK-1029 100 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
Trial: NCT01343407
Drug: Placebo for MK-1029 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six capsules once daily for 5 days in Period 1, and the same in Period 2, 3, or 4 in a crossover design.
Trial: NCT01343407
Drug: Placebo for MK-1029 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
Trial: NCT04619264
Drug: Papacarie
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First, tooth was cleaned with a wet cotton pellet. The gel was inserted using disposable syringe tip into the cavity and its color changed from clear to cloudy indicating the presence of infected tissues. After 40 seconds, the softened carious tissue was removed using excavator by gentle pressure. The remaining gel was removed with a cotton pellet. The procedure was repeated until there was no change in the gel color indicating that there was no more infected tissue.
Trial: NCT01500018
Drug: TC-5214 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT02432040
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, made to look like the interventional drug
Trial: NCT02034747
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01952535
Drug: HMS5552
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01952535
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02656797
Drug: Topical Amphotericin-B 0.4% liposomal gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Amphotericin-B 0.4% liposomal gel
Trial: NCT02672111
Drug: CAM2038 q1w or q4w exposure to SL BPN/NX
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02672111
Drug: CAM2038 q1w or q4w new to BPN treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00467025
Drug: AMG 386 placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 386 placebo IV
Trial: NCT03930641
Drug: RTH258
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg in prefilled syringe
Trial: NCT03641547
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is a chemotherapy drug licensed to treat a number of different types of cancer, it is a noncytotoxic pre-cursor of the cytotoxic 5-fluourouracil. Capecitabine use is not considered standard practice in Stage A2 \& B, therefore Capecitabine is considered an investigational medicinal product for the purpose of this trial.
Trial: NCT01613547
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days
Trial: NCT00671580
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as directed
Trial: NCT02327221
Drug: Ovasave
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
Trial: NCT02327221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
Trial: NCT00589979
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Patch
Trial: NCT02662985
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab placebo was provided in a 1 mL PFS for s.c. injection.
Trial: NCT01486004
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type = exact number, unit = mg, number = 150, form = capsule, route = oral use. Capsule is taken once daily for 10 days (Day12 till and including Day21) in 2nd OC cycle.
Trial: NCT01486004
Drug: Ovysmen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type = exact number, unit = mg, number = 35µg/1mg, form = tablet, route = oral use. 35 µg ethinylestradiol and 1 mg norethindrone once daily for first 21 days in each OC cycle (2 OC cycles in total)
Trial: NCT02056717
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of normal saline 2 mL IV 1 h before UAE
Trial: NCT00931476
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01398072
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: An oral dose of 250 mg once daily three times a week (every other day).
Trial: NCT01398072
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An oral dose of 100 mg once daily.
Trial: NCT03521960
Drug: Buspirone oral capsule
RxNorm normalized name: buspirone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 milligrams, three times daily
Trial: NCT03521960
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 milligrams (placebo), three times daily
Trial: NCT00269737
Drug: Fentanyl Transdermal Therapeutic System (TTS)
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01248494
Drug: BEZ235
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Dose level 1: 400mg PO BID~* Dose level -1: 400mg PO in AM and 200mg PO in PM~* Dose level -2: 200mg PO BID
Trial: NCT01248494
Drug: BKM 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Dose Level 1: BKM120, 100 mg PO daily~* Dose level -1: BKM120, 80 mg PO daily~* Dose Level -2: BKM120, 60 mg PO daily